| 中文名称 | (2S,4S,5S,7S)-5-氨基-N-(3-氨基-2,2-二甲基-3-氧代丙基)-4-羟基-2-异丙基-7-(4-甲氧基-3-( 3-甲氧基丙氧基)苄基)-8-甲基壬酰胺半富马酸盐;阿利克仑半富马酸盐 |
|---|---|
| 英文名称 | Aliskiren Hemifumarate (Synonyms: CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate) |
| CAS号 | 173334-58-2 |
| 分子式 | C34H57N3O10 |
| 分子量 | 667.83 |
| MDL | MFCD10566724 |
| 外观 | White to off-white powder |
| 储存条件 | 4°C, sealed storage, away from moisture |
Aliskiren hemifumarate (CGP 60536; CGP60536B; SPP 100) is an orally active, selective renin inhibitor with an IC50 of 1.5 nM. It is utilized in research pertaining to hypertension, cardiovascular diseases, and cancer cachexia.As a direct renin inhibitor, aliskiren targets the renin-angiotensin-aldosterone system (RAAS), a key pathway in blood pressure regulation. Its role in hypertension management is significant, offering an alternative to traditional antihypertensive medications. Additionally, aliskiren's potential impact on cardiovascular health and cancer cachexia is under investigation, highlighting its broad research applications.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft